Kalaari-backed Affordplan secures Series B funding round from Omidyar Network, others

Affordplan

Fintech startup in the healthcare space, Affordplan has raised Rs 55.8 crore in Series B funding round from Lok Capital and Omidyar Network. The Delhi-based startup also saw a participation of existing investors Prime Venture Partners and Kalaari Capital in the latest financing round.

This is the third round of capital infusion for Affordplan. The startup was a part of Kalaari Capital’s incubator KStart and had earlier raised Rs 3 crore in a seed round in May 2016. Six months later it secures Series A round of $3 million from Prime Venture Partners and Kalaari.

Affordplan was founded in 2015 by Tejbir Singh and Hemal Bhatt, who previously worked at ride-hailing firm Taxiforsure. The startup allows hospitals to provide personalised payment plans to its subscribers which will ultimately result in the patients saving on their future medical treatment. It also offers discounts on tests, consultation charges and medicines as incentives for it.

Also Read: Founders of Alive and Mojo bring their next offering – the ‘Flipkart of medical service’

The fintech platform can be used for non-emergency procedures which can be planned for in advance such as pregnancy, eye care, dental, plastic surgeries and orthopaedic procedures, among others.

Affordplan does not charge any interest from consumers. It makes money by charging hospitals a variable fee based on the procedures patients opt for, and it works with small to mid-sized hospitals. It acts as a collection platform and charges fee from the hospitals they tie up with.

With over 250 hospitals partners, the company operates in 10 cities and it claims to serve over 90,000 patients so far.

Of late, Omidyar Network led $2.8 million seed round in fintech startup Kaleidofin. Earlier, this year, the vc firm also participated in funding rounds of Hyderabad-based NowFloats, parenting startup Healofy and self-publishing startup Pratilipi.

The development was reported by Paper.vc.

Comments

LEAVE A REPLY

Please enter your comment!
Please enter your name here